title: Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
abstract: Anthracyclines are used extensively in the therapy of hematologic malignancies. However, their use has been limited by acute and chronic cardiotoxicity. Cardiac troponins have emerged as sensitive and specific markers of even minor myocardial damage. In this study we prospectively evaluated serial measurements of serum cardiac markers and echocardiography in patients with de novo acute myeloid and lymphoid leukemias (AML and ALL, respectively) treated with anthracyclines. We examined and subdivided 79 patients into 3 groups: group 1 (37 patients with AML, all < 60 years), group 2 (25 with AML, all 260 years), group 3 (17 with ALL). Serum specimens were collected before treatment and during and after therapy and were analyzed for troponin I (Tnl), myoglobin, creatine phosphokinase-muscle myocardium isoenzyme B, and lactate dehydrogenase concentrations. In group 1, 4 of the 37 patients (11%) had increased levels of Tnl on the 14th day of induction therapy, but by the 28th day the Tnl level had returned to normal in 3 of these 4 patients. In group 2, 3 of the 25 patients (12%) demonstrated increased Tnl concentrations on the 7th day of induction therapy, but by the 14th day these levels had normalized in 2 of the 3. In group 3, we detected no increased Tnl concentrations. Echographic study did show a significant correlation with the Tnl levels (P < .001), involving a reversible decrease in left ventricular ejection fraction among patients with increased Tnl levels (> 0.15 ng/mL) on day 14 in group 1 and on day 7 in group 2. These results may aid the clinician in the treatment of patients by identifying high-risk patients who may benefit from closer observation or supportive cardiac therapy.
authors.affiliation: Department of Hematology, University of Foggia, Italy. g.specchia@ematba.uniba.it
authors.forename: Giorgina
authors.initials: G
authors.lastname: Specchia
authors.forename: Caterina
authors.initials: C
authors.lastname: Buquicchio
authors.forename: Nicola
authors.initials: N
authors.lastname: Pansini
authors.forename: Francesca
authors.initials: F
authors.lastname: Di Serio
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Liso
authors.forename: Domenico
authors.initials: D
authors.lastname: Pastore
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Greco
authors.forename: Lucia
authors.initials: L
authors.lastname: Ciuffreda
authors.forename: Anna
authors.initials: A
authors.lastname: Mestice
authors.forename: Arcangelo
authors.initials: A
authors.lastname: Liso
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006331:Heart Diseases / Q000097:blood* / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D019210:Troponin I / Q000097:blood*
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D019210:Troponin I